We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Illustration
Illustration

A new study revealing how antibodies against the SARS-CoV-2 virus can vary among recipients of different COVID-19 vaccines was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The study by researchers at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) shows how antibody responses and adverse reactions can differ in recipients of the Moderna and Pfizer COVID-19 vaccines.

Vaccines have become essential tools in the fight against COVID-19, but it’s still unclear exactly how the antibodies generated from different vaccines change or wane over time. Meanwhile, the spread of the Delta variant and the rising number of breakthrough infections have both highlighted the importance of characterizing antibodies against SARS-CoV-2 in both vaccinated and unvaccinated individuals. Knowing more about antibody patterns could also help clinicians assess individuals’ immunity to SARS-CoV-2, in addition to helping with the diagnosis and management of patients.

In the new study, the researchers collected blood samples of 78 individuals who received the Moderna vaccine and 70 individuals who received the Pfizer vaccine, before the second vaccine dose, 14 days after the second dose, and 30 days after. The study participants also took a survey where they rated the severity of adverse effects and symptoms after vaccination. Overall, individuals who received the Moderna vaccine showed a higher antibody response against the viral spike protein compared with those who received the Pfizer vaccine (4,244 U/mL vs. 1,986 U/mL 30 days after dose two) and also reported stronger side effects. However, the researchers have cautioned that these differences could arise from confounding variables such as the higher mRNA dosage in the Moderna vaccine. The team also found that antibody responses had dropped 30 days after the second dose, regardless of the vaccine given.

“We can’t claim Moderna is better than Pfizer based on these results … but it does seem there is more of a response from Moderna at least in terms of the assay that we used,” said Michael Kelliher, PhD, of Dartmouth-Hitchcock Medical Center, who led the research. “How that correlates with the total adaptive immune response is unknown, and there’s still a decent amount of research that needs to be done on this topic.”

Related Links:
Dartmouth-Hitchcock Medical Center

Gold Supplier
Molecular Diagnostic System
iPonatic
New
Gold Supplier
Centrifuge
Multifuge X4 Pro Centrifuge Series
New
SARS-CoV-2 Antigen Test
Actim SARS-CoV-2
New
Molecular Diagnostic Platform
VERIGENE II System

Print article
AACC

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.